 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

G1 Therapeutics, Inc. (NASDAQ:GTHX  Get Free Report) has been assigned a consensus recommendation of Moderate Buy from the six research firms that are presently covering the...

G1 Therapeutics, Inc. (NASDAQ:GTHX) Given Average Rating of "Moderate Buy" by Analysts

Current Chairman of the Board and industry veteran Mark Velleca appointed CEO CAMBRIDGE, Mass. and NEW YORK, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a...

Black Diamond Therapeutics Announces CEO Transition

RESEARCH TRIANGLE PARK, N.C., Sept. 01, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options...

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Shares of G1 Therapeutics, Inc. (NASDAQ:GTHX Get Free Report) have received a consensus rating of Moderate Buy from the six brokerages that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and five have given a buy ...

G1 Therapeutics, Inc. (NASDAQ:GTHX) Receives $11.80 Consensus Price Target from Analysts

Landscape Capital Management L.L.C. lessened its holdings in shares of G1 Therapeutics, Inc. (NASDAQ:GTHX Free Report) by 31.3% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 38,569 shares of the companys stock after...

G1 Therapeutics, Inc. (NASDAQ:GTHX) Shares Sold by Landscape Capital Management L.L.C.

G1 Therapeutics, Inc. (NASDAQ:GTHX  Free Report)  Research analysts at HC Wainwright boosted their Q3 2023 earnings estimates for shares of G1 Therapeutics in a research report issued on Thursday, August 3rd. HC Wainwright analyst E. White now anticipates that the company will earn ($0...

Q3 2023 Earnings Estimate for G1 Therapeutics, Inc. Issued By HC Wainwright (NASDAQ:GTHX)

G1 Therapeutics, Inc. (NASDAQ:GTHX  Free Report)  Research analysts at Wedbush lifted their Q3 2023 earnings per share (EPS) estimates for G1 Therapeutics in a report released on Wednesday, August 2nd. Wedbush analyst D. Nierengarten now expects that the company will post earnings of...

G1 Therapeutics, Inc. (NASDAQ:GTHX) to Post Q3 2023 Earnings of ($0.24) Per Share, Wedbush Forecasts

Theres a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cerevel Therapeutics Holdings (CERE Research Repor... Theres a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cerevel Therapeutics Holdings (CERE Research Report...

Analysts Are Bullish on Top Healthcare Stocks: Cerevel Therapeutics Holdings (CERE), G1 Therapeutics (GTHX)

- Recognized Total Revenue of $42.4 Million, Including $11.1 Million in Net COSELA (trilaciclib) Revenue - - Reiterated Expectation for Interim Overall Survival (OS) Analysis of Pivotal Phase 3 Trial in Metastatic Triple Negative Breast Cancer (TNBC) in the First Quarter of 2024 - - Presented New ...

G1 Therapeutics Provides Second Quarter 2023 Financial Results and Operational Highlights

G1 Therapeutics Q2 2023 Earnings Preview

G1 Therapeutics, Inc. engages in the development of small molecule therapeutics for the treatment of patients with cancer. Its products pipeline includes trilaciclib, rintodestrant, and lerociclib. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.

Watchers	4,795
52-Wk Low	$1.17
52-Wk High	$13.85

Market Cap	$74.51M
Volume (M)	445,210.00
52-Wk High	$13.85
52-Wk Low	$1.17

GTHX G1 Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals